Tcc denied as experimental or investigational by Humana?

Humana's specific coverage criteria for tcc are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Transcranial Current Stimulation (TCC/tCS) as Experimental

Humana's experimental or investigational denial for transcranial current stimulation reflects its internal clinical policy assessment that the evidence for this treatment modality does not yet meet its defined threshold for established clinical benefit in the specific indication for which it was requested. Humana's coverage policies for neuromodulation therapies vary by indication — a determination of "experimental" for one condition does not automatically apply to all uses, and the evidentiary threshold Humana applies may not align with current peer-reviewed literature or emerging clinical consensus.

This is one of the most commonly appealed denial categories in neuromodulation, and external review outcomes frequently favor patients when the clinical record is well-documented. Independent external reviewers apply current evidence standards — not insurer-internal policy dates — and are required to consider published peer-reviewed literature at the time of review.

## Federal Appeal Rights

Under ACA §2719 and ERISA §503, experimental and investigational denials are explicitly subject to independent external review. If Humana upholds the denial internally, you have the right to an external review by an independent organization, typically within four months of the final internal denial — confirm the exact date from your denial letter. Expedited external review is available when your clinical condition is urgent. State insurance laws in many states provide additional protections for experimental-denial appeals.

## Appeal Process and Timeline

1. Obtain Humana's clinical policy bulletin for the specific indication — this will identify the evidence standard Humana applied and where it believes the evidence is insufficient. 2. File a Level 1 internal appeal with a comprehensive clinical package and a physician letter addressing the evidentiary gaps Humana cited. 3. If denied, file for external review immediately — this is the strongest avenue for experimental denials because independent reviewers are not bound by Humana's internal policy. 4. Consider a simultaneous state insurance department complaint if Humana's policy is clearly inconsistent with current peer-reviewed consensus.

## Documentation to Gather

• Diagnosis and treatment history: Clinical notes confirming the diagnosis and a full record of prior treatments tried, with documented outcomes — establishing the medical context for why transcranial current stimulation was recommended.
• Treating clinician's evidence letter: A letter from your psychiatrist or neurologist that (a) identifies the current state of evidence for transcranial current stimulation in your specific indication, (b) references relevant peer-reviewed publications without citing specific statistics or effect sizes (your physician can characterize the evidence qualitatively), and (c) explains why the treatment is considered an appropriate clinical option by the relevant professional community.
• Professional society position statements: If the applicable specialty society (e.g., the American Psychiatric Association, a relevant neurology society) has issued a position statement or guideline that addresses transcranial current stimulation for your condition, your clinician can reference it.
• Clinical necessity for this patient: Beyond the general evidence argument, document why this specific patient's situation — prior treatment failures, tolerability issues, specific clinical profile — makes transcranial current stimulation the appropriate next step.

## Criteria-Mapping Structure

Obtain the exact evidentiary criteria from Humana's clinical policy bulletin that led to the experimental classification. In your appeal, address each criterion specifically: if Humana requires a certain type of study design or volume of evidence, your physician's letter should speak to the current state of the literature on those specific points. For external review, organize the submission as a clinical brief — diagnosis, treatment history, clinical rationale, evidence summary — that allows the independent reviewer to efficiently evaluate the record.